Initially, ERβ was believed to be the primary subtype in NSCLC, although antiestrogen therapy led to limited clinical efficacy due to the inhibition of ERβ signaling (Garon et al. 2018; Stabile et al. 2011). The gene discussed is ESR2; the disease is non-small cell lung carcinoma.